Patient Monitoring Stocks Q4: Growth & Challenges
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Patient monitoring stocks, including Insulet, iRhythm, DexCom, and ResMed, reported solid Q4 earnings, with Insulet leading growth at 31% and DexCom growing slowest at 13%. Despite beating analyst estimates, shares dropped an average of 16% due to high research costs, strict regulations, and pricing squeezes. AI advancements could boost device smarts and demand amid chronic disease booms, making these stocks worth watching for the next health tech wave.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/18ee06fa869ce781